8 completed. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 3 | Completed 3 |
Follow MorphoSys AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MOR202 for Refractory MN MOR202 - Membranous Nephropathy | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2021-10-22 | 2026-07-13 |
| Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi Tafasitamab, Idelalisib, Venetoclax - Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia | Phase 2 | Completed | MorphoSys AG | 24 | 2016-11-01 | 2021-12-20 |
| Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL Tafasitamab, Lenalidomide - Diffuse Large B-cell Lymphoma | Phase 2 | Completed | MorphoSys AG | 81 | 2016-03-29 | 2023-10-23 |
| Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL MOR00208, lenalidomide, Correlative Studies - Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 41 | 2014-01-17 | 2025-12-15 |
| Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) MOR00208 (formerly Xmab 5574) - Non-Hodgkin Lymphoma | Phase 2 | Completed | MorphoSys AG | 92 | 2013-04-23 | 2023-11-07 |
| Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis MOR103, Placebo - Multiple Sclerosis | Phase 1 / Phase 2 | Completed | MorphoSys AG | 32 | 2012-01-01 | 2014-11-21 |
| A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma MOR03087 phase 1 dose escalation, MOR03087, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | MorphoSys AG | 91 | 2011-07-01 | 2021-11-16 |
| Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis MOR103 - Rheumatoid Arthritis | Phase 1 / Phase 2 | Completed | MorphoSys AG | 96 | 2009-12-01 | 2014-10-24 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Arthritis, Rheumatoid (1) · Glomerulonephritis, Membranous (1) · Leukemia, Prolymphocytic (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Multiple Sclerosis (1)
tafasitamab (4) · Lenalidomide (3) · Otilimab (2) · felzartamab (2) · Dexamethasone (1) · idelalisib (1) · pomalidomide (1) · venetoclax (1)
Germany (6) · Poland (5) · Italy (4) · United States (4) · United Kingdom (3) · Austria (2) · Belgium (2) · Hungary (2) · Spain (2) · Bulgaria (1) · Czechia (1) · France (1) · Netherlands (1) · Ukraine (1)
Roman P Korolkiewicz, MD, PhD (2) · Anke Muth (1) · Giuseppe Remuzzi, MD (1) · Jennifer Woyach, MD (1) · Johannes Duell, MD (1)
PMID 24534756, PMID 29444231, PMID 32171061, PMID 32511983, PMID 34196165, PMID 34414843, PMID 34433649, PMID 34779360, PMID 35674661, PMID 35861632, PMID 37646664, PMID 42027554
2014 (1)